Journal
CLINICAL INFECTIOUS DISEASES
Volume 51, Issue -, Pages S120-S125Publisher
OXFORD UNIV PRESS INC
DOI: 10.1086/653060
Keywords
-
Categories
Funding
- Astra-Zeneca
- Bayer
- Covidien
- US Food and Drug Administration
- Infectious Diseases Society of America
- American College of Chest Physicians
- American Thoracic Society
- Society of Critical Care Medicine
- Pharmaceutical Research and Manufacturers of America
- AstraZeneca Pharmaceuticals
- Forest Pharmaceuticals
Ask authors/readers for more resources
Appropriate end points are crucial for the successful interpretation of clinical trials. Choosing end points for therapeutic trials of ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) requires careful consideration, because they are complications of critical illness. It may be difficult to distinguish the consequences of VAP and HAP from manifestations of the underlying illnesses, and it is important to determine their incremental magnitude, to plan for possible treatment effects and, thus, sample size calculations. In this article, we discuss mortality, attributable mortality, and time to clinical events as possible end points for HAP and/or VAP trials. Because of the paucity of evidence on HAP, we focus predominantly on VAP. In a systematic review of applicable trials, VAP appears to have slight intensive care unit and low hospital-attributable mortality. VAP is associated with prolonged durations of intensive care unit stay, hospital stay, and mechanical ventilation. Because of these findings, superiority trials of VAP treatment that use mortality as a primary end point are not possible. Equivalency studies are possible, but there are sample size implications. The use of time to clinical event end points, especially when combined with mortality, may be the best option for trial in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available